ClinicalTrials.Veeva

Menu

A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus (PRELUDE)

Teva Pharmaceuticals logo

Teva Pharmaceuticals

Status and phase

Terminated
Phase 2

Conditions

Systemic Lupus Erythematosus

Treatments

Drug: edratide

Study type

Interventional

Funder types

Industry

Identifiers

NCT00203151
TV-4710/201

Details and patient eligibility

About

It is thought that Edratide may be able to reduce the symptoms of SLE.

Enrollment

340 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Willing and able to give written informed consent
  2. Between the ages of 18 and 65 years (inclusive)
  3. Fulfilled at least 4 ACR classification criteria
  4. SLE patients with moderate, active disease
  5. Subjects on stable dose of SLE medications for at least 4 weeks before randomization.
  6. Women of child-bearing potential must practice a medically acceptable method of contraception..
  7. Must understand the requirements of the study and agree to comply with the study protocol.

Exclusion criteria

  1. Any condition which the investigator feels may interfere with participation in the study.
  2. Subjects having a history of chronic infection
  3. Subjects with a history of immunodeficiency syndrome or malignancy,
  4. Subjects who received any investigational medication (including DHEA) within 3 months prior to randomization,
  5. Subjects treated with any cytotoxic agents in the 3 months prior to randomization.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

340 participants in 2 patient groups, including a placebo group

1
Experimental group
Treatment:
Drug: edratide
2
Placebo Comparator group
Treatment:
Drug: edratide

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems